New obesity drug AMG 133 enters human testing
NCT ID NCT06976372
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial tested an experimental drug called AMG 133 in 120 adults with overweight or obesity. Participants received multiple doses of the drug or a placebo to see how the body processes it and to check for safety issues. The study did not aim to measure weight loss directly, but to gather important information for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AMG 133 (an experimental drug given as a shot under the skin)
What this could lead to
If successful, this could lead to a new weight-loss medication for people with overweight or obesity.
What could go wrong
This is an early Phase 1 study focused on drug levels and safety, not weight loss. The drug may cause side effects or not work as hoped in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExel
Anaheim, California, 92801, United States
-
CenExel Collaborative Neuroscience Research, LLC Los Alamitos
Los Alamitos, California, 90720, United States
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247, United States